Company
Exonics
- Status
- Acquiredas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Exonics discovers and develops medicines for the treatment of neuromuscular diseases. The Company develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of Duchenne muscular dystrophy mutations. Exonics was acquired by Vertex on June 6, 2019 for up to $1B.
About the company
- Status notes
- Exonics was acquired by Vertex on June 6, 2019 for up to $1B.
Exit
- Acquisition
- 2019-06-06up to $1B
Loading relationship preview